Cortendo Invest AB is conducting a pioneering R&D programme aimed at introducing totally new treatments that break the link between stress and cardiovascular disease.

Cortendo Invest AB has with CORT001 carried out a double blind placebo controlled, FDA approved phase IIa study, with positive results. For more information, see “Clinical Studies”.

Cortendo Invest AB will now enter into a phase IIb study and expected time for start is 2004. The main aim of the study is to study the effect of treatment during longer time period.